Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;25(3):220-231.
doi: 10.1111/iju.13512. Epub 2017 Dec 20.

Current treatment strategies for advanced prostate cancer

Kazumasa Komura  1 , Christopher J Sweeney  2 , Teruo Inamoto  1 , Naokazu Ibuki  1 , Haruhito Azuma  1 , Philip W Kantoff  3
Affiliations
Review

Current treatment strategies for advanced prostate cancer

Kazumasa Komura et al. Int J Urol. 2018 Mar.

Abstract

During the past decade, treatment strategies for patients with advanced prostate cancer involving stage IV (T4N0M0, N1M0 or M1) hormone-sensitive prostate cancer and recurrent prostate cancer after treatment with curative intent, as well as castration-resistant prostate cancer, have extensively evolved with the introduction and approval of several new agents including sipuleucel-T, radium-223, abiraterone, enzalutamide and cabazitaxel, all of which have shown significant improvement on overall survival. The appropriate use of these agents and the proper sequencing of these agents are still not optimized. The results of several recently reported randomized controlled trials and retrospective studies could assist in developing a treatment strategy for advanced prostate cancer. In addition, prospective studies and molecular characterization of tumors to address these issues are ongoing.

Keywords: castration-resistant prostate cancer; precision medicine; prostate cancer; sequential therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosure Statement

P.W.K. is a scientific advisory or data safety monitoring board member for Astellas, Bayer, Bellicum, BIND Biosciences, BN Immonotherapeutics, DRGT, Genetech/Roche, Ipsen Pharmaceuticals, Janssen, Metamark (no longer in business), Merck, MTG Therapeutics, New England Research Institutes, Omnitura, OncoCellMDX, OncoGenex, Progeniry, Sanofi, Tarveda Therapeutics, and Thermo Fisher, and has investment interest with Bellicum, DRGT, and Tarveda Therapeutics. C.J.S. has received consulting fees from Astellas, Bayer, Genetech, Janssen, Pfizer, and Sanofi, and has received research fundings from Astellas, Janssen, Sotio, and Sanofi.

Figures

Figure 1
Figure 1
See this image and copyright information in PMC

Comment in

References

    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67:7–30. - PubMed
    1. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513–20. - PubMed
    1. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502–12. - PubMed
    1. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147–54. - PubMed
    1. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005. - PMC - PubMed

MeSH terms